Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

Is Bio Age Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? Laiba Immad Tue, June 30, 2026 at 8:09 PM GMT+7 2 min read BIOA We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Bio Age Labs, Inc. (NASDAQ:BIOA) is one of the best low-priced pharma stocks on this list.

The Fly reported on June 16 that BIOA announced the dosing of the first participant in QUELL-CV, a Phase 2 proof-of-concept study evaluating BGE-102. The investigational therapy is a potent, orally available, brain-penetrant small molecule NLRP3 inhibitor designed for once-daily administration. BIOA is developing BGE-102 with cardiovascular risk reduction as its lead therapeutic focus. The initiation of the QUELL-CV trial represents progress in advancing the company's clinical program targeting cardiovascular disease pathways.

BioAge Labs, Inc. (NASDAQ:BIOA) previously reported its first quarter 2026 financial results on May 8, highlighting the continued advancement of its therapeutic programs focused on cardiometabolic diseases and aging biology. The company shared progress from its BGE-102 program, where Phase 1 data showed strong reductions in hsCRP levels, including median decreases of 86% from baseline across evaluated dose groups. BGE-102 was well tolerated with no serious adverse events reported. BIOA plans to begin a Phase 2 dose-ranging study in participants with elevated cardiovascular risk in mid-2026. During the quarter, collaboration revenue reached $2.8 million, while research and development expenses increased to $20.4 million. As of March 31, 2026, BIOA held approximately $384.9 million in cash, cash equivalents, and marketable securities.